Page 1
Page 1
NASH and Nutritional Therapy
This collection of research and clinical findings on nonalcoholic steatchepatitis (NASH) and nutritional therapy contains significant new findings in several fields . As NASH frequently causes liver cirrhosis, the nutritional aspects of its treatment are discussed . Other areas covered include nonalcoholic fatty liver, the role of leptin in the pathogenesis of NASH, restricted diets and exercise therapy, mammalian targets of the peptide rapamycin, and genetic factors influencing the development of NASH.
Imaging of the liver and Intra-hepatic biliary tract ; Vol.2 : Tumoral pathologies
This is the second of two volumes that together provide a comprehensive analysis of the embryology, normal anatomy, and pathology of the liver and intrahepatic biliary tract as seen on modern diagnostic imaging techniques. In this second volume, readers will find comprehensive description and illustration of the imaging appearances of tumoral pathologies, both in the “normal liver” and in the context of chronic liver disease and liver cirrhosis. In addition, the imaging findings in relation to different treatment approaches are presented, with extensive coverage of imaging of tumor response and post-treatment changes.
Cirrhosis and New Treatment
The liver organ in the human body is located in the abdominal-pelvic space below the diaphragm. It is responsible for metabolic functions. This research talks about the liver anatomy and its functions as well as the liver cirrhosis that defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury that leads to portal hypertension and end stage liver disease. Recent advances in the understanding of the natural history and pathophysiology of cirrhosis, and in treatment of its complications, resulting in improved management, quality of life and life expectancy of cirrhotic patients. At present, liver transplantation remains the only curative option for a selected group of patients, but pharmacological therapies that can halt progression to decompensated cirrhosis or even reverse cirrhosis are currently being developed.
